RPS23P1 and Alzheimer disease: Since RPS23RG1 levels are found to be decreased in AD, our findings indicate that RPS23RG1 and its downstream pathways may be developed further as potential therapeutic targets in AD, thus providing a new avenue for AD research intended to identify effective cures.